Navigation Links
UCSF researchers identify new drug target for Kaposi's sarcoma
Date:7/30/2009

UCSF researchers have identified a new potential drug target for the herpes virus that causes Kaposi's sarcoma, re-opening the possibility of using the class of drugs called protease inhibitors against the full herpes family of viruses, which for 20 years has been deemed too difficult to attain.

The new drug target, which is known as a protease dimer, could serve as a model for developing new therapeutics for diseases ranging from cancer to Alzheimer's, the researchers say. Findings are reported in the Advance Online Publication section of the "Nature Chemical Biology" web site and can be found at www.nature.com/nchembio/index.html.

Most current antiviral drugs target the active sites of viral proteins, where enzymes and receptors work in a lock-and-key approach to either activate or deactivate that particular protein, the researchers explained. Traditionally, drug development has focused on inhibiting that lock-and-key action to prevent the enzyme, or receptor from being effective.

Some viral enzymes known as proteases, however, including those for HIV and the herpes virus family, take the form of a dimer, or two identical halves much like a fully opened clamshell in their most stable state. Those proteases play an essential role in making the virus infectious, but require the two clamshell halves to bind together to be activated, according to the paper.

The HIV protease was successfully targeted for drug development in the 1980s, by blocking the active site on the surface of the dimer, but the herpes virus protease dimer has consistently eluded efforts to disrupt it at its active site, the researchers said.

The UCSF team set out to find ways to instead prevent the two halves of the dimer from connecting at that clamshell joint, to prevent it from activating. What they found was a new target on the unstable, monomer form of the protease, which respond
'/>"/>

Contact: Kristen Bole
kbole@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Fox Chase researchers uncover one force behind the MYC oncogene in many cancers
2. 1 in 6 health workers wont report in flu pandemic -- study by Ben-Gurion U. researchers
3. Researchers team up to provide new hope for childhood hunger
4. UBC researchers help push for standard DNA barcodes for plants
5. Researchers develop brain-reading methods
6. ISU researchers find possible treatment for spinal muscular atrophy
7. Researchers capture bacterial infection on film
8. Researchers design first model motor nerve system thats insulated and organized like the human body
9. Iowa State University researchers develop process for surgical genetic changes
10. UCLA researchers discover new molecular pathway for targeting cancer, disease
11. Munich researchers discover new target for tailored antibiotics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/25/2015)... and BELLEVUE, Wash. , ... in advanced robotic systems, announced today it will unveil ... ground vehicle (UGV), at the National Tactical Officers Association ... The Guardian S is the first-ever commercially ... of years of research and in-field trials and is ...
(Date:8/20/2015)... Calif. , Aug. 20, 2015   ... focused on improving the user experience and security ... vision technologies, today announced that its TrulySecure™ ... biometric authentication software to be FIDO Certified™. ... TrulySecure for compliance with the FIDO UAF (Universal ...
(Date:8/18/2015)... , Aug. 17, 2015 Research ... addition of the "Global Biometric Authentication & ... - Estimation & Forecast, 2015-2020" report to ... authentication and identification systems market is expected to ... 2015 to 2020 and generate over $25 billion ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
... of two tiny marine algae, a team of scientists ... research in algal physiology, plant biology, and marine ecology. ... Monterey Bay Aquarium Research Institute (MBARI) and the Joint ... effort between MBARI, JGI, and an international consortium of ...
... CREEK, Calif. Scientists from two-dozen research organizations led by ... (JGI) and the Monterey Bay Aquarium Research Institute (MBARI) ... genes enabling them to capture carbon and maintain its ... a team led by Alexandra Z. Worden of MBARI ...
... North Carolina at Chapel Hill School of Medicine have identified ... the most deadly types of cancer, and discovered how a ... and potential treatment apply to a type of brain tumor ... larger group of brain tumors called malignant gliomas, which is ...
Cached Biology News:Genes from tiny marine algae suggest unsuspected avenues for new research 2Genes from tiny marine algae suggest unsuspected avenues for new research 3Genes from tiny marine algae suggest unsuspected avenues for new research 4Genes from tiny algae shed light on big role managing carbon in world's oceans 2Genes from tiny algae shed light on big role managing carbon in world's oceans 3UNC study: Scientists identify chemical compound that may stop deadly brain tumors 2
(Date:8/31/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/v7fdpx/argentina ) has announced ... - Growth, Trends & Forecasts (2014-2020)" report to ... market is estimated at $0.17 billion by 2018 at ... The near future will bring Biomedical sensors that ... These sensors can be set to trigger alerts when ...
(Date:8/31/2015)...  For people with Down syndrome, news from ... company, located in the Science + Technology Park at ... therapies yet for people with Down syndrome and other chromosome ... syndrome and Edwards syndrome aneuploidies in human cell cultures, ... Elixirgen plans to develop this technology into a treatment ...
(Date:8/31/2015)... SHANGHAI , Aug. 31, 2015  MicuRx ... antibiotics, today announced positive top-line results from the ... drug candidate MRX-I. MRX-I is an oral oxazolidinone ... MRSA and VRE, while offering physicians and patients ... currently available oxazolidinone agents. "These ...
(Date:8/31/2015)... ... August 31, 2015 , ... Regulatory agencies ... the drug development approval process. Thus, innovator companies must understand what will be ... a Chicago-based CMO, has been hosting multiple educational panels and seminars for experts ...
Breaking Biology Technology:Argentina Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts 2014-2020 2New Down syndrome therapy discovered 2MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3
... Mich., April 16 Lycera Corp. today announced it ... which is developing novel small-molecule pharmaceuticals to treat autoimmune ... has received $10 million as a first tranche of ... proceeds in two tranches as specific milestones are met. ...
... Bioscience Inc have successfully implemented Amphora,s PatentSafe solution ... using PatentSafe as a fully electronic lab notebook, ... more efficiently into today,s laboratories but it also ... simply and effectively, saving significant time previously spent ...
... One,Medical, Inc. ("China Sky One Medical" or "the Company") ... company producing over-the-counter,drugs in the People,s Republic of China ... and fiscal year ended December 31,2008. , , ... -- Total revenues increased 104.0% year-over-year to $26.0 million, ...
Cached Biology Technology:Lycera Closes $36 Million Series A Financing 2Lycera Closes $36 Million Series A Financing 3Lycera Closes $36 Million Series A Financing 4Solidus Bioscience Protect their Research and Improve Efficiency With Amphora's PatentSafe Solution 2Solidus Bioscience Protect their Research and Improve Efficiency With Amphora's PatentSafe Solution 3China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 2China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 3China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 4China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 5China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 6China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 7China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 8China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 9China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2008 Results 10
...
... the first biological reagent that ... and not just by inhibiting ... anti-mycoplasma agent that can be ... directly. The cytotoxicity of Mynox ...
... can be used to label ... covalently bound acridinium NHS ester ... presence of hydrogen peroxide. Acridinium ... used as a detection method ...
... mobility shift assay (EMSA) is a powerful ... to as gel shift or gel retardation, ... that when subjected to electrophoresis, free DNA ... The Pierce LightShift Chemiluminescent EMSA Kit is ...
Biology Products: